MedPath

Staging LaParoscopy to Assess Lymph NOde InvoLvement in Advanced GAstric Cancer

Not Applicable
Recruiting
Conditions
Gastric Cancer
Lymph Node Metastasis
Registration Number
NCT05720598
Lead Sponsor
Medical University of Lublin
Brief Summary

Staging LaParscopy to Assess Lymph NOde InvoLvement in Advanced GAstric Cancer (POLA) study aims to investigate the safety and feasibility of ICG-guided SN retrieval in GC patients undergoing multimodal treatment. The pretreatment clinical variables potentially associated with the procedure will also be analyzed.

To the best of our knowledge, the current study is the first to evaluate the role of ICG in SN biopsy in advanced GC patients undergoing multimodal treatment.

Detailed Description

Comprehensive lymph node assessment seems to be critical for proper treatment strategy and survival prediction, particularly in advanced GC. Recent data on the sentinel node (SN) concept in early GC has shown favorable results regarding LN detection rate and clinical status determination. Staging laparoscopy (SL) with lavage cytology provides an additional value to the clinical staging of GC, particularly in detecting occult peritoneal disease. The role of Indocyanine green (ICG) guided SN mapping in GC confirmed its technical feasibility. ICG can be safely used to identify SN, determine the surgical resection line, improve the LN harvest, and reduce noncompliance in patients undergoing D2 lymphadenectomy.

The majority of the studies focused on the aspect of the increase in LN harvest. At the same time, no data exist regarding its potential role in GC nodal staging. To the best of our knowledge, the current study is the first to evaluate the role of ICG in SN biopsy in advanced GC patients undergoing multimodal treatment.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
190
Inclusion Criteria
  1. Age ≥ 18 years
  2. Histologically confirmed gastric adenocarcinoma (or undifferentiated carcinoma)
  3. Stage II - III disease (cT2-4a, N0-3, M0) based on the pretreatment CT and 8th edition of TNM classification
  4. Qualification for SL by the decision of the multidisciplinary tumor board
  5. Written informed consent for endoscopy and SL
Exclusion Criteria
  1. Early GC (cT1N0-3M0) scheduled for endoscopic treatment by the multidisciplinary tumor board
  2. Previous abdominal surgery which could interfere lymphatic basin of the stomach, including previous gastrectomy, endoscopic (sub)mucosal dissection
  3. Distant metastasis (cM1) clinically apparent in pretreatment abdominal/pelvic CT
  4. Technical inability to perform endoscopic ICG injection or ICG injection beyond the submucosa
  5. Visual inability to identify the SN during SL
  6. Positive cytology (cyt+) after SL
  7. Other malignancies
  8. History of allergy to iodine agents

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
The primary endpoint of this study is the identification rate of ICG-guided SN in advanced GC patients.Up to 2 weeks after inclusion in the study, during staging laparoscopy

The identification rate will allow confirmation of the safety and feasibility of ICG-guided SN biopsy during staging laparosocpy in advanced GC patients

Secondary Outcome Measures
NameTimeMethod
Pathological status and regression grade of the retrieved sentinel node after neoadjuvant chemotherapyUp to 2 weeks after gastrectomy, 1 month after completion of neoadjuvant chemotherapy and 3 months after initial staging laparoscopy

SN retrieved during gastrectomy will undergo microscopic evaluation. The histopathological report will contain information on the character of the lymph node (benign/metastatic) and its regression grade according to Becker classification

Pathological status of the retrieved sentinel nodeUp to 2 weeks after staging laparoscopy

SN retrieved during staging laparoscopy will undergo microscopic evaluation. The histopathological report will contain information on the character of the lymph node (benign/metastatic)

Trial Locations

Locations (1)

Medical University of Lublin

🇵🇱

Lublin, Poland

Medical University of Lublin
🇵🇱Lublin, Poland
Karol RawiczPruszyński, Professor
Contact
81 531 81 26
karol.rawicz-pruszynski@umlub.pl

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.